Pathway to Artificial Pancreas Systems Revisited: Moving Downstream

Artificial pancreas (AP) systems, a long-sought quest to replicate mechanically islet physiology that is lost in diabetes, are reaching the clinic, and the potential of automating insulin delivery is about to be realized. Significant progress has been made, and the safety and feasibility of AP systems have been demonstrated in the clinical research center and more recently in outpatient “real-world” environments. An iterative road map to AP system development has guided AP research since 2009, but progress in the field indicates that it needs updating. While it is now clear that AP systems are technically feasible, it remains much less certain that they will be widely adopted by clinicians and patients. Ultimately, the true success of AP systems will be defined by successful integration into the diabetes health care system and by the ultimate metric: improved diabetes outcomes.

[1]  [The endocrine pancreas. From the isolated islet to the "artificial pancreas" (author's transl)]. , 1976, MMW, Munchener medizinische Wochenschrift.

[2]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[3]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[4]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[5]  P. Raskin,et al.  Improved Glycemic Control in Intensively Treated Type 1 Diabetic Patients Using Blood Glucose Meters With Storage Capability and Computer-Assisted Analyses , 1998, Diabetes Care.

[6]  E. Vivian,et al.  Pramlintide for the Treatment of Diabetes Mellitus , 2003, The Annals of pharmacotherapy.

[7]  Eric Charles,et al.  [Insulin pumps]. , 2005, Revue de l'infirmiere.

[8]  Bruce W Bode,et al.  Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. , 2005, Diabetes care.

[9]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[10]  Michael O'Grady,et al.  Continuous glucose monitoring and intensive treatment of type 1 diabetes. , 2008, The New England journal of medicine.

[11]  Howard Wolpert,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group , 2008 .

[12]  Nigel H Lovell,et al.  The use of an Energy Monitor in the management of diabetes: a pilot study. , 2009, Diabetes technology & therapeutics.

[13]  Aaron J. Kowalski,et al.  Juvenile Diabetes Research Foundation Artificial Pancreas Consortium Update , 2009, Journal of diabetes science and technology.

[14]  Aaron J. Kowalski,et al.  Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. , 2009, Diabetes technology & therapeutics.

[15]  A. Lin,et al.  Psychosocial Well-Being and Functional Outcomes in Youth With Type 1 Diabetes 12 years After Disease Onset , 2010, Diabetes Care.

[16]  Roy W Beck,et al.  Variation of Interstitial Glucose Measurements Assessed by Continuous Glucose Monitors in Healthy, Nondiabetic Individuals , 2010, Diabetes Care.

[17]  W. Kenneth Ward,et al.  A Controlled Study of the Effectiveness of an Adaptive Closed-Loop Algorithm to Minimize Corticosteroid-Induced Stress Hyperglycemia in Type 1 Diabetes , 2011, Journal of diabetes science and technology.

[18]  D. Edgerton,et al.  Physiologic action of glucagon on liver glucose metabolism , 2011, Diabetes, obesity & metabolism.

[19]  A. Penfornis,et al.  The potential role of glucagon‐like peptide‐1 or its analogues in enhancing glycaemic control in critically ill adult patients , 2011, Diabetes, obesity & metabolism.

[20]  Anirban Roy,et al.  Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.

[21]  Kellee M Miller,et al.  The T1D Exchange clinic registry. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  Howard C. Zisser,et al.  Fully Integrated Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes.

[23]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[24]  T. Jones,et al.  Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. , 2013, JAMA.

[25]  Darrell M. Wilson,et al.  Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. , 2013, Diabetes technology & therapeutics.

[26]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[27]  D. Klonoff,et al.  Threshold-based insulin-pump interruption for reduction of hypoglycemia. , 2013, The New England journal of medicine.

[28]  Aaron J. Kowalski,et al.  It's time to move from the A1c to better metrics for diabetes control. , 2013, Diabetes technology & therapeutics.

[29]  R. Beck,et al.  Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry , 2013, Pediatric diabetes.

[30]  J. Winikoff,et al.  Who needs an artificial pancreas? (怎样的患者需要一个人工胰腺？) , 2013, Journal of diabetes.

[31]  Marc D. Breton,et al.  Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas , 2014, Diabetes Care.

[32]  Roman Hovorka,et al.  Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study , 2014, Diabetes Care.

[33]  W. Kenneth Ward,et al.  Automated Control of an Adaptive Bihormonal, Dual-Sensor Artificial Pancreas and Evaluation During Inpatient Studies , 2014, IEEE Transactions on Biomedical Engineering.

[34]  Eyal Dassau,et al.  Design and in silico evaluation of an intraperitoneal-subcutaneous (IP-SC) artificial pancreas , 2014, Comput. Chem. Eng..

[35]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[36]  Eyal Dassau,et al.  Annals of the New York Academy of Sciences the Artificial Pancreas: Current Status and Future Prospects in the Management of Diabetes , 2022 .

[37]  W. Tamborlane,et al.  The Artificial Pancreas: Are We There Yet? , 2014, Diabetes Care.

[38]  Darrell M. Wilson,et al.  A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes , 2014, Diabetes Care.

[39]  A population-based study of risk factors for severe hypoglycemia in a contemporary cohort of childhood-onset type 1 diabetes , 2014 .

[40]  Ahmad Haidar,et al.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[41]  D. BretonMarc,et al.  Multinight "bedside" closed-loop control for patients with type 1 diabetes. , 2015 .

[42]  B. Anderson,et al.  A Review of the Mental Health Issues of Diabetes Conference , 2015, Diabetes Care.

[43]  S. Wild,et al.  Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. , 2015, JAMA.

[44]  Rajiv V Shah,et al.  Retrospective analysis of the real-world use of the threshold suspend feature of sensor-augmented insulin pumps. , 2015, Diabetes technology & therapeutics.

[45]  Multinight "bedside" closed-loop control for patients with type 1 diabetes. , 2015, Diabetes technology & therapeutics.

[46]  Glucagon in the Artificial Pancreas , 2014, Journal of diabetes science and technology.

[47]  J. Skyler.  T1DM in 2014: Progress towards a bionic pancreas , 2015, Nature Reviews Endocrinology.

[48]  The next best thing to a cure. , 2015, Time.

[49]  M R Lasarev,et al.  Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes. , 2015, Journal of diabetes and its complications.